Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

IntroductionSeveral forces are contributing to an increase in the number of people living with and surviving colorectal cancer (CRC). However, due to the lack of available data, little is known about the implications of these forces. In recent years, the use of administrative records to inform research has been increasing. The aim of this paper is to investigate the potential contribution that administrative data could have on the health economic research of CRC.MethodsTo achieve this aim, we conducted a systematic review of the health economic CRC literature published in the United Kingdom and Europe within the last decade (2009-2019).ResultsThirty-seven relevant studies were identified and divided into economic evaluations, cost of illness studies and cost consequence analyses.ConclusionsThe use of administrative data, including cancer registry, screening and hospital records, within the health economic research of CRC is commonplace. However, we found that this data often come from regional databases, which reduces the generalisability of results. Further, administrative data appear less able to contribute towards understanding the wider and indirect costs associated with the disease. We explore several ways in which various sources of administrative data could enhance future research in this area.

Original publication

DOI

10.1111/ecc.13477

Type

Journal article

Journal

European journal of cancer care

Publication Date

09/2021

Volume

30

Addresses

Edinburgh Health Economics, University of Edinburgh, Edinburgh, UK.

Keywords

Humans, Colorectal Neoplasms, Mass Screening, Cost-Benefit Analysis, Europe, United Kingdom